Product Description
Pneumococcal Conjugate Vaccines
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EpicentRx
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Pneumonia, Pneumococcal|Pneumococcal Infections|Communicable Diseases|Malnutrition
Phase 3: Meningitis, Haemophilus|Acute Respiratory Distress Syndrome|Measles|Sneezing|Maternal Death|Influenza, Human|Meningitis, Pneumococcal|Nasopharyngeal Diseases|Vision, Low|Pneumonia, Pneumococcal|Bacteremia|Sepsis|Pneumonia|Meningitis|Otitis Media
Phase 2: HIV Infections|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
fPCV | P4 |
Completed |
Pneumonia, Pneumococcal|Malnutrition |
2023-03-14 |
|
PCV1+1_FU | N/A |
Completed |
Pneumonia|Meningitis |
2022-12-01 |
|
FPCV | P4 |
Completed |
Communicable Diseases|Pneumonia, Pneumococcal|Pneumococcal Infections |
2022-09-30 |
|
PICRcarriage | N/A |
Unknown status |
Pneumonia, Pneumococcal |
2020-08-01 |